APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Recruiting now · Phase 2
Conditions studied: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
In brief
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)
Key facts
- Study ID
- NCT03175224
- Run by
- Apollomics Inc.
- People needed
- 497
- Starts
- 2017-09-27
- Expected to finish
- 2026-11-30
- Last updated by the study team
- 2025-06-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Royal Marsden Hospital - Surrey — Surrey Quays, United Kingdom (enrolling)
- University College London Hospital — London, United Kingdom (enrolling)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (enrolling)
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California, United States (enrolling)
- University of North Carolina — Chapel Hill, North Carolina, United States (enrolling)
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States (enrolling)
- University of Wisconsin — Madison, Wisconsin, United States (enrolling)
- St Vincents Hospital Melbourne — Melbourne, Australia (enrolling)
- Cross Cancer Institute — Edmonton, Canada (enrolling)
- McGill University Health Center - Research Institute — Montreal, Canada (enrolling)
- Princess Margaret Hospital — Toronto, Canada (enrolling)
- Cancer Care Manitoba — Winnipeg, Canada (enrolling)
- CHRU de Brest - Hôpital Morvan — Brest, France (enrolling)
- Centre Leon Berard — Lyon, France (enrolling)
- Centre d'Essais Precoces en Cancerologie de Marseille — Marseille, France (enrolling)
- Hopital Bichat - Claude Bernard - AP-HP — Paris, France (enrolling)
- Gustave Roussy — Villejuif, France (enrolling)
- Orszagos Koranyi Pulmonologiai Intezet — Budapest, Hungary (enrolling)
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz — Tatabánya, Hungary (enrolling)
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola — Bologna, Italy (enrolling)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola, Italy (enrolling)
- IRCCS Ospedale San Raffaele — Milan, Italy (enrolling)
- Istituto Europeo di Oncologia — Milan, Italy (enrolling)
- Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera — Padova, Italy (enrolling)
- National Cancer Centre Singapore — Singapore, Singapore (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.